medigraphic.com
Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado

2011, Number 3

<< Back Next >>

Rev Esp Med Quir 2011; 16 (3)

Frequency of left ventricular hypertrophy in patients with stroke

Pérez ZJM, Trejo GA, Velasco LÓG, García BV

Language: Spanish
References: 32
Page: 146-151
PDF size: 322.36 Kb.


ABSTRACT

Background: Cerebral vascular disease is the fourth leading cause of death in our country. The risk in patients with left ventricular hypertrophy is associated with a ratio of probability of up to 3.0.
Objective: To determine the frequency of left ventricular hypertrophy in patients with cerebrovascular disease, in a hospital of third level of ISSSTE.
Patients and method: We performed an observational, prospective, descriptive and transversal study in patients hospitalized for more than 72 hours with ischemic and hemorrhagic cerebral vascular disease diagnosis, with the left ventricular mass index determined by echocardiography of Troy. We registered antecedents of hypertension, diabetes, and dyslipidemia, and body mass index to determine obesity, and associated them with cerebral vascular disease with left ventricular hypertrophy.
Results: We included 59 patients with age average of 70 years old, 66% of them were women, and 34% male. Left ventricular hypertrophy was found in 51% of the patients with CVD, of which 73% were women and 27% men, the median age was 63 years. The type of events found was ischemic in 74% and hemorrhagic in 26%. Left ventricular hypertrophy associated with other risks factors such as: hypertension (67%), diabetes mellitus (27%), obesity (30%) and dyslipidemia (50%).
Conclusions: Left ventricular hypertrophy occurs in one of every two patients with cerebral vascular disease, so it is important the prevention and control of cardiovascular risk factors to reduce the incidence of stroke with high rate of morbidity and mortality.


REFERENCES

  1. INEGI. Principales causas de mortalidad general. México: Secretaría de Salud, 2005.

  2. Carreño JE, Apaolaza F, Ocaranza MP, Jalil JE. Hipertrofia cardiaca: eventos moleculares y celulares. Rev Esp Cardiol 2006;59(5):473-486.

  3. Hill JA, Olson EN. Cardiac plasticity. N Engl J Med 2008;358:1370-1380.

  4. Lorell BH, Carabello BA. Left ventricular hypertrophy: Pathogenesis, detection, and prognosis. Circulation 2000;102:470-479.

  5. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study. N Engl J Med 1990;322:1561-1566.

  6. Guadalajara JF. Entendiendo la hipertrofia ventricular izquierda. Arch Cardiol Mex 2007;77:175-180.

  7. González JR, Cea L, Bertomeu V, Aznar J, en representación de los investigadores del estudio VIIDA. Criterios electrocardiográficos de hipertrofia ventricular izquierda y perfil de riesgo cardiovascular en hipertensos. Estudio VIIDA. Rev Esp Cardiol 2007;60(2):148-156.

  8. McFarland TM, Alam M, Goldstein S, Pickard SD, Stein PD. Echocardiography diagnosis of left ventricular hypertrophy. Circulation 1978;57:1140-1144.

  9. Alfakih K, Walters K, Jones T, Ridgway J, et al. New genderspecific partition values for ECG criteria of left ventricular hypertrophy recalibration against cardiac MRI. Hypertension 2004;44:175-179.

  10. Edvardsen T. Regional diastolic dysfunction in individuals with left ventricular hypertrophy measured by tagged magnetic resonance Imaging. The Multi-Ethnic Study of Atherosclerosis (MESA). Am Heart J 2006;151(1):109-114.

  11. Friedman GD, Loveland DB, Ehrlich SP Jr. Relationship of stroke to other cardiovascular disease. Circulation 1968;38:533-541.

  12. Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994;90:1786-1793.

  13. Lozano JV, Redón J, Cea L y González J, en representación del grupo de los investigadores del estudio ERIC-HTA 2003. Hipertrofia ventricular izquierda en la población hipertensa española. Estudio ERIC-HTA. Rev Esp Cardiol 2006;59(2):136-142.

  14. Verdecchia P, Porcellati C, Reboldi G, Gattobigio R, et al. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circulation 2001;104:2039-2044.

  15. Bikkina M, Levy D, Evans JC, Larsson MG, et al. Left ventricular mass and risk of stroke in an elderly cohort. The Framingham Heart Study. JAMA 1994;272:33-36.

  16. Brown MM, Wade JP, Marshall J. Fundamental importance of arterial oxygen content in the regulation of cerebral blood flow in man. Brain 1985;108:81-93.

  17. National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular disease III. Stroke 1990;21:637-741.

  18. Thom T, Haase N, Rosamond W, Howard VJ, et al. Heart disease and stroke statistics-2006 Update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006;113:e85-e151.

  19. Osborn AG. Stroke. In: Osborn AG, Maack J, editors. Diagnostic Neuroradiology. St. Louis: Mosby, 1994;330-398.

  20. Lee SH. Stroke. In: Lee SH, Zimmerman RA, editors. Cranial MRI and CT. 4th ed. New York: McGraw-Hill, 1999;557-594.

  21. Osborn AG. Ictus. Angiografía cerebral. 2a ed. Madrid: Marbán, 2000;381-403.

  22. Pons-Lladó G, Carreras F, Borrás X, Llauger J, Palmer J. Estudio comparativo entre métodos ecocardiográficos y de resonancia magnética en el cálculo de la masa ventricular izquierda. Rev Esp Cardiol 2001;54:22-28.

  23. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, et al. Echocardiography assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986;57:450-458.

  24. Lang RM, Bierig M, Devereux RB, Flachskampf FA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-1463.

  25. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr. Body mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999;341(15):1097-1105.

  26. Devereux RB. Left ventricular mass and stroke: what is the connection? JAMA 1994;272:71-72.

  27. Okin PM, Roman MJ, Devereux RB, Kligfield P. Association of carotid atherosclerosis with electrocardiographic myocardial ischemia and left ventricular hypertrophy. Hypertension 1996;28:3-7.

  28. Bahemuka M. Primary intracerebral hemorrhage and heart weight: a clinicopathologic case-control review of 218 patients. Stroke 1987;18:531-536.

  29. Deza L, Aldave R, Barrera J. Historia natural de la enfermedad vascular cerebral en Perú: estudio intrahospitalario de 1517 pacientes. Rev Neuro-Psiquiatr 2001;64(2):105-132.

  30. Yip P, Jeng J, Lee T, Chang Y, et al. Subtypes of ischemic stroke: A hospital-based stroke registry in Taiwan (SCAN-IV). Stroke 1997;28:2507-2512.

  31. Devereux RB, Dahlof B, Gerdts E. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Trial. Circulation 2004;110;1456-1462.

  32. Aguilar C, Ventura F, Rodríguez-Delfín L. El aumento de la expresión del ARNm de la enzima convertidora de angiotensina I homóloga (ECA-2) inducido por atorvastatina se asocia a menor fibrosis e hipertrofia ventricular izquierda en un modelo de cardiomiopatía diabética. Rev Perú Med Exp Salud Pública 2011;28(2):264-272.




2020     |     www.medigraphic.com